Celebrating a Decade of the World ADC Awards – Winners Announcement
Taking place during the 14th World ADC San Diego, the 10th World ADC Awards reunited both newcomers and leaders of the antibody-drug conjugate industry this October 18, 2023. Celebrating a decade of honoring the very best in ADC development, hundreds of attendees shared in a special gala after the second conference day.
Hosted by the World ADC Team in partnership with Ambrx, the ceremony was a perfect opportunity to recognize recent successes, long-term commitment to the field and upcoming pioneers who have gone above and beyond to ensure the continued success of ADCs.
With over 1000 votes casted and many scientific proposals drafted, the expert judging panel selected the winners and runners up across 10 categories highlighting amazing individual work, extraordinary endeavors, teamwork, and commercial acumen.
List of Winners Below:
- Best ADC Platform Technology: Winner: LegoChem Biosciences
Runner Up: Catalent SMARTag
Shortlisted: Abzena, Ajinomoto Bio-Pharma Services, Genequantum Healthcare, WuXi XDC, Synaffix - Most Promising Clinical Candidate: Winner: Enfortumab vedotin (PADCEV) – Seagen/Astellas
Runners Up: BL-B01D1 – SystImmune, Patritumab deruxtecan – Daiichi Sankyo
Shortlisted: ARX788 – Ambrx, Datopotamab deruxtecan – AstraZeneca / Daiichi Sankyo, Farletuzumab Ecteribulin – Eisai / Bristol Myers-Squibb, Ziloveramab vedotin – Merck & Co. - Best New Drug Developer: Winner: Exelixis
Runner Up: Duality Biologics
Shortlisted: Ambrx, Eisai, Genequantum Healthcare, Iksuda Therapeutics - Best Contract Research Organization: Winner: NJ Bio,
Runner Up: Charles River Laboratories
Shortlisted: Abzena, ChemExpress, Eurofins, PPD, Pharmaron, Sterling Pharma Solutions - Best Contract Manufacturing Development Organization: Winner: WuXi XDC
Runners Up: Lonza, BSP Pharmaceuticals
Shortlisted: Axplora, MilliporeSigma, Piramal Pharma Solutions - Best ADC Preclinical Publication 2022: Winner: Discovery of BT8009: A Nectin-4 Targeting Bicycle Toxin Conjugate for the Treatment of Cancer
Runner Up: Targeting LRRC15 Inhibits Metastatic Dissemination of Ovarian Cancer - Best ADC Clinical Publication 2022: Winner: Trastuzumab deruxtecan in Previously Treated HER2-Positive Breast Cancer
Runner Up: Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer - Outstanding Academic Investigator Award: Winner: Nathan Tumey, Binghampton University
- The George R Pettit Individual Input to the Field Award: Winner: Shanu Modi, Memorial Sloan Kettering Cancer Center
- Long Standing Contribution to the Field Award: Winner: Puja Sapra
Each year, during the World ADC Awards’s team alongside a panel of independent judges select scientists, researchers, and drug developers who are progressing ADCs to the front- line as life-changing treatments for those patients diagnosed with cancer.
For more information about World ADC San Diego and the World ADC Awards please visit: www.worldadc-usa.com and www.worldadc-awards.com